America and Britain Sign No-Tariff Agreement on Prescription Drugs.
The United Kingdom and the United States have secured a significant trade agreement that will maintain zero levies on UK medicine exports entering the US market.
Agreement Details of the Accord
As part of the deal, the UK has committed to boost expenditure on drugs through the National Health Service (NHS). This commitment ensures that import taxes on these crucial products will be held at nothing for a timeframe of three years.
This development comes after earlier statements to dramatically increase tariffs on branded pharmaceutical imports, with potential rates mentioned up to 100%.
"This deal between the Britain strengthens the international landscape for cutting-edge drugs and introduces much-needed balance to transatlantic medicine commerce," a statement noted.
Trade Importance
Pharmaceuticals represent one of the the United Kingdom's largest exports to the US, which is easily the biggest market for leading companies like GSK and AstraZeneca.
Statistics indicate that in the one-year period to the end of September, the UK exported medicines worth over eleven billion pounds to the US. This value made up 17.4% of all goods exports in that period.
"This guarantee secures employment, boosts investment and facilitates the UK to establish itself as a global hub for life sciences," the Business and Trade Secretary remarked.
Specific NHS Changes
The agreement involves several specific changes from the UK:
- Higher Cost Ceiling: The UK will lift the affordability limit at which it judges new therapies to be too expensive by a quarter.
- Higher Drug Budget: There is a goal to raise total health service expenditure on drugs from 0.3% of Gross Domestic Product to 0.6% over the following ten-year period.
- Payback Limit: The percentage manufacturers must refund to the NHS to prevent overspending will be restricted at 15%. In the past, rebates were more than 20%.
Industry Background
The deal takes place against a long-running row between the drug companies and the UK government over medicine costs and regulatory access.
This friction were intensified by claims that American consumers were paying a premium for the equivalent treatments than patients in the other developed nations.
In recent months, several major drug company projects in the UK have been halted or scrapped, while multi-billion-dollar funding commitments have been directed toward American operations.
The Science Minister acknowledged that the NHS needed to spend more on drugs, noting that its expenditure on drugs had declined as a proportion of its overall budget over the last ten years.
